Cue Biopharma, Inc. financial data

Symbol
CUE on Nasdaq
Industry
Pharmaceutical Preparations
Location
40 Guest Street, Boston, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Imagen Biopharma, Inc. (to 6/19/2015)
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 217 % -41.5%
Debt-to-equity 83.3 % +44.1%
Return On Equity -172 % -53.3%
Return On Assets -93.9 % -32%
Operating Margin -447 % +53%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 61.8M shares +27.1%
Common Stock, Shares, Outstanding 61.8M shares +30.9%
Entity Public Float 59.9M USD -61.2%
Common Stock, Value, Issued 62K USD +31.9%
Weighted Average Number of Shares Outstanding, Basic 56.3M shares +23.1%
Weighted Average Number of Shares Outstanding, Diluted 56.3M shares +23.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 9.29M USD +69.2%
Research and Development Expense 36.3M USD -11%
General and Administrative Expense 14.6M USD -12.6%
Operating Income (Loss) -41.5M USD +20.4%
Nonoperating Income (Expense) 826K USD -41.7%
Net Income (Loss) Attributable to Parent -40.7M USD +19.8%
Earnings Per Share, Basic -0.72 USD/shares +35.1%
Earnings Per Share, Diluted -0.72 USD/shares +35.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 22.5M USD -53.7%
Accounts Receivable, after Allowance for Credit Loss, Current 945K USD -44.3%
Assets, Current 25.1M USD -51.1%
Property, Plant and Equipment, Net 471K USD -40.8%
Operating Lease, Right-of-Use Asset 4.37M USD -30.9%
Other Assets, Noncurrent 105K USD -10.3%
Assets 32.2M USD -47.7%
Accounts Payable, Current 2.82M USD -19.4%
Accrued Liabilities, Current 2.91M USD -29.7%
Liabilities, Current 13.7M USD -19.9%
Operating Lease, Liability, Noncurrent 1M USD -68.3%
Liabilities 14.7M USD -39.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -342M USD -13.5%
Stockholders' Equity Attributable to Parent 17.5M USD -52.8%
Liabilities and Equity 32.2M USD -47.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.78M USD +9.68%
Net Cash Provided by (Used in) Financing Activities 2.35M USD +507%
Net Cash Provided by (Used in) Investing Activities -55K USD -100%
Common Stock, Shares Authorized 200M shares +100%
Common Stock, Shares, Issued 61.8M shares +30.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -7.49M USD -264%
Interest Paid, Excluding Capitalized Interest, Operating Activities 209K USD -36.7%
Deferred Tax Assets, Valuation Allowance 94M USD +11.8%
Deferred Tax Assets, Gross 95.2M USD +10.9%
Operating Lease, Liability 4.54M USD -30.4%
Depreciation 385K USD -29.4%
Payments to Acquire Property, Plant, and Equipment 55K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -40.7M USD +19.7%
Lessee, Operating Lease, Liability, to be Paid 4.77M USD -31.7%
Property, Plant and Equipment, Gross 4.15M USD -5.89%
Operating Lease, Liability, Current 3.54M USD +5.11%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.23M USD -55.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.54M USD +105007%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure +16%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 231K USD -49.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 0 USD
Deferred Tax Assets, Operating Loss Carryforwards 58.1M USD +8.89%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 3.14M USD +7.21%
Lessee, Operating Lease, Liability, to be Paid, Year Four 818K USD
Operating Lease, Payments 709K USD +139%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.21M USD -32.2%
Share-based Payment Arrangement, Expense 6.85M USD -16.3%
Interest Expense 100K USD -14.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%